

Topic 003 - Recurrence Rates are Significantly Higher than Generally Perceived

Traditional Nomagrams have carried PC Recurrence Predictions out as far as 7 or 10 years.

Recent studies reveal that PC recurrence *continues* out as far as 25 years after primary treatment.

The Sub-Topics:

[Topic 003.1 – Simplified Survival – Mean Percentages Only](#)

[Topic 003.2 – Survival Table Including Confidence Intervals](#)

[Topic 003.3 - Example State Diagram – Oncovance 40 PC Disease States](#)

Topic 003.1 – Simplified Survival – Mean Percentages Only

Table 3. Estimate of the Risk of Prostate Cancer–Specific Survival After Biochemical Recurrence Following Radical Prostatectomy

Prostate-Specific Antigen Doubling Time, mo	Risk Estimate, % (95% Confidence Interval)			
	Recurrence >3 y After Surgery		Recurrence ≤3 y After Surgery	
	Gleason Score <8	Gleason Score ≥8	Gleason Score <8	Gleason Score ≥8
5-yr Estimate	(Mean Estimates of <u>NOT</u> Dying <u>OF</u> Prostate Cancer Specifically)			
≥ 15.0	100%	99	99	98
9.0 – 14.9	99	98	97	94
3.0 – 8.9	97	94	91	81
< 3.0	92	83	74	51
10-yr Estimate				
≥ 15.0	98	96	93	86
9.0 – 14.9	95	90	85	69
3.0 – 8.9	84	68	55	26
< 3.0	59	30	15	1
15-yr Estimate				
≥ 15.0	94	87	81	62
9.0 – 14.9	86	72	59	31
3.0 – 8.9	59	30	16	1
< 3.0	19	2	<1	<1%

(Reprinted) JAMA, July 27, 2005 – Vol 294, No. 4

Topic 003.2 - Survival

Table 3. Estimate of the Risk of Prostate Cancer–Specific Survival After Biochemical Recurrence Following Radical Prostatectomy

Prostate-Specific Antigen Doubling Time, mo	Risk Estimate, % (95% Confidence Interval)			
	Recurrence >3 y After Surgery		Recurrence ≤3 y After Surgery	
	Gleason Score <8	Gleason Score ≥8	Gleason Score <8	Gleason Score ≥8
5-y Estimate				
≥15.0	100 (98 to 100)	99 (98 to 99)	99 (96 to 100)	98 (90 to 100)
9.0-14.9	99 (70 to 100)	98 (75 to 100)	97 (76 to 100)	94 (63 to 99)
3.0-8.9	97 (81 to 100)	94 (74 to 99)	91 (67 to 98)	81 (46 to 95)
<3.0	92 (70 to 98)	83 (52 to 96)	74 (37 to 93)	51 (19 to 82)
10-y Estimate				
≥15.0	98 (96 to 100)	96 (93 to 98)	93 (80 to 98)	86 (61 to 96)
9.0-14.9	95 (75 to 99)	90 (58 to 98)	85 (49 to 97)	69 (30 to 92)
3.0-8.9	84 (62 to 94)	68 (37 to 89)	55 (25 to 82)	26 (7 to 62)
<3.0	59 (29 to 83)	30 (10 to 63)	15 (3 to 53)	1 (<1 to 55)
15-y Estimate				
≥15.0	94 (87 to 100)	87 (79 to 92)	81 (57 to 93)	62 (32 to 85)
9.0-14.9	86 (57 to 97)	72 (35 to 92)	59 (24 to 87)	31 (7 to 72)
3.0-8.9	59 (32 to 81)	30 (10 to 63)	16 (4 to 49)	1 (<1 to 51)
<3.0	19 (5 to 51)	2 (<1 to 38)	<1 (<1 to 26)	<1 (<1 to 2)

(Reprinted) JAMA, July 27, 2005—Vol 294, No. 4

Topic 003.3 - Example State Diagram – Oncovance 40 PC Disease States

